Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 4

1(20.0%)

Phase 3

1(20.0%)

Phase 1

1(20.0%)

5Total

Phase 2(2)

Phase 4(1)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00489255Phase 4Completed

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment

Role: collaborator

NCT01073228Phase 2Completed

Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease

Role: collaborator

NCT01537666Phase 1Completed

Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics

Role: collaborator

NCT00878553Phase 2Completed

Study of Sleep-maintenance Activity of 3 Doses of SKP-1041

Role: collaborator

NCT00255983Phase 3Terminated

A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis

Role: collaborator

All 5 trials loaded